Atlas Trials

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Clinical trial NCT04708210 · UNKNOWN

Trial details

NCT number
NCT04708210
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Malignant Tumors
Start date
2021-04-28
Primary completion
2022-12-21
Enrollment
256

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.